|
Aug 6
|
Warner Bros. earnings, Fed talk, jobless claims: What to Watch
|
|
Aug 6
|
LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme.
|
|
Aug 6
|
Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday
|
|
Aug 6
|
Is It Time to Buy Biotech Stocks?
|
|
Aug 6
|
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
|
|
Aug 6
|
Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?
|
|
Aug 6
|
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
|
|
Aug 6
|
Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi
|
|
Aug 6
|
Novo Nordisk Stock Is Dropping After Earnings. It Got Worse.
|
|
Aug 6
|
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
|
|
Aug 6
|
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
|
|
Aug 6
|
Novo pushes back against obesity drug compounders as competition intensifies
|
|
Aug 6
|
Eli Lilly and Co (LLY) Traded Lower in Q2 Despite Good Results
|
|
Aug 6
|
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings
|
|
Aug 6
|
Novo Nordisk reports second quarter earnings missing Wall Street estimates on slower GLP-1 sales
|
|
Aug 6
|
Wegovy maker Novo Nordisk to cut costs as competition grows
|
|
Aug 6
|
Is Wall Street Bullish or Bearish on Eli Lilly Stock?
|
|
Aug 6
|
Novo CFO: US Wegovy, Ozempic Prices to Keep Falling
|
|
Aug 6
|
Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.
|
|
Aug 6
|
Disney Earnings, New Tariff Deadline, Fed Speakers: Still to Come This Week
|